,

Translational Neuroimmunology in Multiple Sclerosis

From Disease Mechanisms to Clinical Applications

Specificaties
Gebonden, blz. | Engels
Elsevier Science | e druk, 2016
ISBN13: 9780128019146
Rubricering
Elsevier Science e druk, 2016 9780128019146
Verwachte levertijd ongeveer 9 werkdagen

Samenvatting

Multiple sclerosis (MS) is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS does not currently exist, therapies can help treat MS attacks, attenuate disease activity, reduce progress of the disease, and manage symptoms.

Translational Neuroimmunology in Multiple Sclerosis provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis, from experimental models and the human disease to the translation of this research to immunotherapeutic strategies. Chapters describe genetic and environmental factors underlying the disease pathogenesis of MS as a basis for development of immunotherapies, immunological markers of disease activity, pharmacogenetics, and responses to therapy. Immunomodulatory therapies currently in practice and future therapeutic strategies on the horizon—such as neuroprotective strategies, stem cells, and repair promotion—are discussed. Contributed by renowned leaders in the field, this cross-disciplinary volume is a great resource for basic scientists and clinical practitioners in neuroscience, neurology, immunology, pharmacology, and in-drug development.

Specificaties

ISBN13:9780128019146
Taal:Engels
Bindwijze:Gebonden

Inhoudsopgave

<p>Section I:  MS Pathology and Mechanisms<br>1. MS Pathology: Inflammation versus Neurodegeneration<br>2. Immune Dysregulation in Multiple Sclerosis<br>3. CNS immune regulation<br>4. Genetics of Multiple Sclerosis<br>5. MS Subtypes: How the Natural History of MS was Challenged Due to Treatment<br>6. Pediatric-Onset MS as a Window into Early Disease Targets and Mechanisms<br>7. Sex-related factors in multiple sclerosis</p> <p>Section II:  Other Patho-Mechanisms<br>8. Environmental Factors and their regulation of immunity in MS<br>9. Gut Microbiota in Multiple Sclerosis: A Bioreactor driving Brain Autoimmunity<br>10. Neuroendocrine Checkpoints of Innate Immune Responses in Multiple Sclerosis: Reciprocal Interactions Between Body and Brain<br>11. Fighting chronic neuroinflammation by boosting autoimmunity: the distinction between neurodegenerative diseases and multiple sclerosis<br>12. Neuroactive steroids and Neuroinflammation</p> <p>Section III:  Surrogate Markers in Multiple Sclerosis<br>13. Surrogate Markers in Multiple Sclerosis: The Role of MRI</p> <p>Section IV:  Currently Approved Therapies – Injectable<br>14. Interferon β in Multiple Sclerosis: A Review<br>15. Glatiramer Acetate - From Bench to Bed and Back<br>16. Natalizumab<br>17. Alemtuzumab (Campath-1H)<br>18. Currently approved DMDs-injectable: cytotoxic immunosuppressive drugs</p> <p>Section V:  Currently Approved DMDs – Oral <br>19. Fingolimod (Gilenya)<br>20. Oral Dimethyl Fumarate (BG-12; Tecfidera®) for Multiple Sclerosis<br>21. Emerging Therapies for Multiple Sclerosis</p> <p>Section VI:  Symptomatic and Complementary Treatments<br>22. Treatment of acute relapses in Multiple sclerosis<br>23. Shedding light on Vitamin D and MS<br>24. Symptomatic and Complementary Treatments <br>25. Cognitive Impairment in Multiple Sclerosis</p> <p>Section VII:  Novel and Emerging Strategies<br>26. Personalized Medicine and Theranostics: Applications to Multiple Sclerosis<br>27. Stem cell based-therapies, remyelination and repair promotion, in the treatment of multiple sclerosis<br>28. Stem cells in Multiple Sclerosis<br>29. T cell vaccination: An insight into T cell regulation<br>30. Reversal of Misfortune: Therapeutic Strategies on the Horizon</p>

Rubrieken

    Personen

      Trefwoorden

        Translational Neuroimmunology in Multiple Sclerosis